30 Mar GSK Announces Arexvy Updated Indication
On March 12, the FDA approved an expanded age indication for AREXVY to include adults aged 18-49 years at increased risk for RSV-LRTD. The FDA also added a limitation of use that AREXVY is not for use in pregnant individuals. Log in to read the specific updates to the USPI.